產品名稱：Pro-Gastrin-releasing peptide, ProGRP Human ELISA Kit
- 產品編號
- BEK1255
- 產品規格
- 96T
- 價格
- 2400.00
- 來源
- -
- 交叉反應
- Human
- 免 疫 原
- -
- 產品簡介
- This kit was based on sandwich enzyme-linked immune-sorbent assay technology. Anti-ProGRP monoclonal antibody was pre-coated onto 96-well plates. The standards and test samples were added to the wells and any ProGRP present is bound by the immobilized antibody. After washing away any unbound substances, the HRP conjugated anti-ProGRP monoclonal antibody was added to wells as detection antibodies. Following a wash to remove any unbound antibody-enzyme reagent, the TMB substrates were added to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding stop solution. The density of yellow is proportional to the ProGRP amount of sample captured in plate. Read the O.D. absorbance at 450nm in a microplate reader, and then the concentration of ProGRP can be calculated.
Kit components
1. One 96-well plate pre-coated with anti-human ProGRP antibody
2. Lyophilized human ProGRP standards: 2 tubes (10 ng / tube)
3. Sample / Standard diluent buffer: 30 ml
4. HRP conjugated anti-human ProGRP antibody (Concentrated): 130 μl. Dilution: 1:100 (Store at 4℃, do NOT store it at -20℃)
5. Antibody diluent buffer: 12 ml
6. TMB substrate: 10 ml
7. Stop solution: 10 ml
8. Wash buffer: 30 ml (25x). Dilution: 1:25
Note: Reconstitute standards and test samples with Kit Component 3.
- 產品別名
- -
- 產品成分
- -
- 檢測范圍
- 31.2 pg/ml - 2000 pg/ml
- 檢測樣品
- For quantitative detection of human ProGRP?in?serum, plasma, cell culture supernatants?or tissue homogenate.
- 產品應用
- ELISA
- 保存條件
- Store at 2-8℃ for 6 months, or at -20℃ for one year.
- 背景資料
- Progastrin-releasing peptide (proGRP) is a recently identified biomarker of small cell lung cancer (SCLC). Plasma proGRP level could be a useful diagnostic and therapeutic monitoring biomarker for patients with SCLC and the initial level may help with SCLC tumor staging. ProGRP was highly expressed in NCI-H446 cells and xenograft tissue. It could be used as a marker for quality control in sample processing and storage in biobanks. Korse CM1 et al study concluded that a high-risk proGRP level (more than twice the upper reference value) in patients with well-differentiated neuroendocrine tumours, WDNETs is a strong indication for a primary tumour in the lung. Besides CgA, proGRP is a complementary tumour marker for prognosis and treatment monitoring in patients with neuroendocrine tumour.
- 參考資料
- 1. Oh HJ, Park HY, Kim KH, Park CK, Shin HJ, Lim JH, Kwon YS, Oh IJ, Kim YI, Lim SC, Kim YC, Kim SH, Shin MG. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer. J Thorac Dis. 2016 Sep;8(9):2530-2537. 2. Hong Z, Shi Y, Liu Z, Zhou X, Yang Y, Tang J. Preliminary radioimmunoimaging and biodistribution of 131iodine-labeled single-chain antibody fragment against progastrin-releasing peptide (31-98) in small cell lung cancer xenografts. Chin Med J (Engl). 2014;127(11):2007-11. 3. Kim SY, Kim JS, Hwang SH, Park HK, Lee JH, Lee DH, Hah SS, Park do Y. Progastrin-releasing peptide is a candidate marker for quality control in clinical sample processing and storage. Am J Clin Pathol. 2012 Feb;137(2):277-82. 4. Korse CM1, Taal BG, Bonfrer JM, Vincent A, van Velthuysen ML, Baas P. An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival. Ann Oncol. 2011 Dec;22(12):2625-30.
